Fundraising Fox
Glycologix
Beverly, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into Glycologix
Sign up to see every warm intro you have to Glycologix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Glycologix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Glycologix is a clinical-stage biotechnology company developing locally delivered biopolymers that mimic natural proteoglycans for the protection and repair of soft tissues. Its lead program, GLX-100, targets interstitial cystitis/bladder pain syndrome (IC/BPS), with the technology intended for additional soft tissue indications.
Founders & leadership
Glycologix was founded in 2021 by Thomas Jozefiak.
TJ
Thomas JozefiakCo-FounderThomas Jozefiak is a co-founder of Glycologix and an R&D consultant with expertise in biomaterials and polymer therapeutics, holding numerous patents and publications in resorbable biomaterials, polymer chemistry, and drug delivery. He has previously co-founded clinical-stage biotechnology companies and held leadership roles in both small and large organizations working on medical devices and drug delivery applications.
DD
Dan DeardorfCEODan Deardorf is CEO of Glycologix, a clinical-stage biotechnology company developing locally delivered biopolymers for soft tissue protection and repair. He brings over 20 years of biopharma experience in product development, business development, and commercial operations at companies including Genzyme and Flexion Therapeutics, and holds an MBA from Wharton.
RH
Rich HeidebrachtVP, Research + Development
Board
GA
George AdaniyaCo-Founder
MF
Martha FarmerBoard director
MM
Michael MarshBoard director
MC
Michael ChesterBoard director
Investors · 1
Cortado Ventureslisted by Cortado VenturesOklahoma City
How we know: Cortado Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.2M disclosed across 4 rounds · 2021–2025
▶$800KraisedDec 2025 · 30 investors · Other TechnologyRule 506(b)
▶$800KraisedDec 2025 · 30 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- George AdaniyaDirector
- Daniel DeardorfExecutive Officer, Director
- Martha FarmerDirector
- Michael MarshDirector
- Michael ChesterDirector
- Offering amount
- $1M
- Amount sold
- $800K
- Minimum investment
- $1
- Proceeds to insiders
- $250K
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedApr 2024 · 48 investors · Other TechnologyRule 506(b)
▶$1.5MraisedApr 2024 · 48 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel DeardorfExecutive Officer, Director
- Douglas SmithExecutive Officer
- Michael MarshDirector
- Michael ChesterDirector
- Martha FarmerDirector
- George AdaniyaDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $5K
- Proceeds to insiders
- $200K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedMay 2023 · 25 investors · Other TechnologyRule 506(b)
▶$1.1MraisedMay 2023 · 25 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- George AdaniyaDirector
- Daniel DeardorfExecutive Officer
- Michael ChesterDirector
- Martha FarmerDirector
- Offering amount
- $1.8M
- Amount sold
- $1.1M
- Minimum investment
- $4.9K
- Proceeds to insiders
- $200K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.8MraisedJan 2022 · 28 investors · Other TechnologyRule 506(b)
▶$1.8MraisedJan 2022 · 28 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Michael ChesterDirector
- George AdaniyaDirector
- Daniel DeardorfExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.8M
- Proceeds to insiders
- $225K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
AbiologicsAbiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
PeptilogicsPeptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.
MediLogixMEDILOGIX is a tech-enabled healthcare services platform for medical equipment management, offering rental management, field operations tools, analytics portals, and proprietary products such as CareMatt for care providers. It serves post-acute care facilities in the United States, with software including MxMobile, MxPortal, and its rental-as-a-service (RaaS) offering.
MedlogixMedlogix provides end-to-end medical claims management and cost containment solutions for property and casualty insurers, including auto liability, workers' compensation, and personal injury protection. The company serves the top national carriers and regional TPAs through its proprietary MyMedlogix cloud platform, which integrates bill review, utilization review, independent medical examinations, and case management.
TrivascularEndologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures. The company serves physicians and patients with vascular conditions, and offers virtual reality-based procedural training for physicians.
Companies working in the same space as Glycologix.
In the news
Frequently asked questions
- What does Glycologix do?
- Glycologix is a clinical-stage biotechnology company developing locally delivered biopolymers that mimic natural proteoglycans for the protection and repair of soft tissues. Its lead program, GLX-100, targets interstitial cystitis/bladder pain syndrome (IC/BPS), with the technology intended for additional soft tissue indications.
- Who founded Glycologix?
- Glycologix was founded by Thomas Jozefiak in 2021.
- Who are Glycologix's investors?
- Glycologix's investors include Cortado Ventures.
- How much funding has Glycologix raised?
- Glycologix has disclosed $5.2M raised across 4 rounds.
- Where is Glycologix headquartered?
- Glycologix is headquartered in Beverly, US.